Sex-Specific Lung Cancer Therapy: Multi-Omics Networks
- Here's a breakdown of the key findings regarding sex-biased drug responses from the provided text, referencing Figure 5B:
- * Danusertib (Aurora Kinase Inhibitor): Showed significantly greater inhibitory effects in female LUAD cell lines compared to male cell lines (p-value = 0.0021).
- In summary: The study found several drugs with significantly different responses based on the sex of the LUAD cell lines, consistent with the sex-biased signaling network analysis conducted.
Here’s a breakdown of the key findings regarding sex-biased drug responses from the provided text, referencing Figure 5B:
* Danusertib (Aurora Kinase Inhibitor): Showed significantly greater inhibitory effects in female LUAD cell lines compared to male cell lines (p-value = 0.0021). This aligns with higher AURKA activity observed in females.
* Beclomethasone (NR3C1 Agonist): Demonstrated higher sensitivity in female cell lines (p-value = 0.0025), supporting the finding that males have stronger NR3C1 activity. Other synthetic corticosteroids showed similar results.
* Sex Steroid Hormone Receptors (AR and ESR1): Were differentially targeted by various modulators, agonists, and destabilizers (p-values < 0.05).
* MAPK14 and MAPK1 inhibitors: Exhibited sex-biased effects (p-values < 0.05).
* PCI-34,051 (HDAC Inhibitor): Showed significantly higher sensitivity in male LUAD cell lines compared to females (p-value = 0.0137).
In summary: The study found several drugs with significantly different responses based on the sex of the LUAD cell lines, consistent with the sex-biased signaling network analysis conducted. Female cell lines generally responded better to drugs targeting AURKA and NR3C1, while male cell lines showed a better response to the HDAC inhibitor PCI-34,051.